Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGCR | P04035 | 1/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.42 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.42 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.37 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.37 |
| ▸ | CPT2 | P23786 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.33 |
| ▸ | GGT1 | P19440 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.32 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.31 |
| ▸ | ARG1 | P05089 | 1/20 | 0.31 |
| ▸ | ARG2 | P78540 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8466854 | 0.80 | HMGCR (0.41) | HMGCRCHRM1TBXA2RADRA1AKDM4E | |
| SCHEMBL6591641 | 0.78 | ALOX15 (0.39) | HMGCRCHRM1TBXA2RADRA1AKDM4E | |
| SCHEMBL8656249 | 0.78 | TSHR (0.59) | HMGCRCHRM1TBXA2RADRA1AKDM4E | |
| SCHEMBL8395320 | 0.77 | DGAT1 (0.47) | TSHRCYP2D6DGAT1TDP1 | |
| SCHEMBL485564 | 0.76 | — | — | |
| SCHEMBL161121 | 0.76 | HMGCR (0.46) | HMGCRCHRM1TBXA2RADRA1AKDM4E | |
| SCHEMBL485077 | 0.76 | — | — | |
| SCHEMBL12116983 | 0.76 | — | — | |
| SCHEMBL16638803 | 0.76 | — | — | |
| SCHEMBL3117265 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 353 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2305624-B1 | Self-degradable explosive device | MAXAMCORP HOLDING SL (ES) | 2017-09-27 | — | — | EP | claimed |
| US-8585841-B2 | Systems and methods for chemical and/or mechanical remediation of nitro compounds and nitrate esters | MAXAMCORP HOLDING S.L. (ES) | 2013-11-19 | — | — | US | claimed |
| EP-2445852-A1 | SYSTEMS AND METHODS FOR CHEMICAL AND/OR MECHANICAL REMEDIATION OF NITRO COMPOUNDS AND NITRATE ESTERS | Maxamcorp Holding, S.L. (ES) | 2012-05-02 | — | — | EP | claimed |
| EP-2305624-A1 | Self-degradable explosive formulations | Maxamcorp Holding, S.L. (ES) | 2011-04-06 | — | — | EP | claimed |
| US-20110041718-A1 | SYSTEMS AND METHODS FOR CHEMICAL AND/OR MECHANICAL REMEDIATION OF NITRO COMPOUNDS AND NITRATE ESTERS | MAXAMCORP HOLDING S.L. (ES) | 2011-02-24 | — | — | US | claimed |
| WO-2010149750-A1 | SYSTEMS AND METHODS FOR CHEMICAL AND/OR MECHANICAL REMEDIATION OF NITRO COMPOUNDS AND NITRATE ESTERS | MAXAMCORP HOLDING S.L. (ES) | 2010-12-29 | — | — | WO | claimed |
| EP-1773311-A1 | A GASTRIC RETAINED DOSAGE FORM OF GABAPENTIN | Depomed, Inc. (US) | 2007-04-18 | — | — | EP | claimed |
| WO-2006015294-A1 | A GASTRIC RETAINED DOSAGE FORM OF GABAPENTIN | DEPOMED, INC. (US) | 2006-02-09 | — | — | WO | claimed |
| WO-2006002031-A1 | SUSTAINED RELEASE DOSAGE FORMS | ANDRX CORPORATION (US) | 2006-01-05 | — | — | WO | claimed |
| US-20050276849-A1 | Sustained release dosage forms | ANDRX CORPORATION | 2005-12-15 | — | — | US | claimed |
| WO-2004112746-A1 | CONTROLLED RELEASE-DRUG DELIVERY SYSTEM FOR ORAL ADMINISTRATION | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2004-12-29 | — | — | WO | claimed |
| US-5540945-A | Pharmaceutical preparations for oral administration that are adapted to release the drug at appropriate sites in the intestines | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 1996-07-30 | — | — | US | claimed |
| US-20240075103-A1 | EXTENDED RELEASE OF NEUREGULIN FOR IMPROVED CARDIAC FUNCTION | ZENSUN SHANGHAI SCIENCE & TECH CO LTD (CN) | 2024-03-07 | — | — | US | disclosed |
| US-11717483-B2 | Controlled release dosage form with enhanced pharmacokinetics | OSMOTICA KERESKEDELMI ES SZOLGALTATO KFT (HU) | 2023-08-08 | — | — | US | disclosed |
| US-11679088-B2 | Controlled release dosage form | OSMOTICA KERESKEDELMI ES SZOLGALTATO KFT (HU) | 2023-06-20 | — | — | US | disclosed |
| US-11638746-B2 | Extended release of neuregulin for improved cardiac function | ZENSUN (SHANGHAI) SCIENCE & TECHNOLOGY, CO., LTD. (CN) | 2023-05-02 | — | — | US | disclosed |
| EP-0169105-A2 | Controlled porosity osmotic pump | MERCK & CO. INC. (US) | 1986-01-22 | — | — | EP | disclosed |
| US-4484921-A | Theophylline therapy utilizing osmotic delivery | ALZA CORPORATION (US) | 1984-11-27 | — | — | US | disclosed |
| US-4439195-A | Theophylline therapy | ALZA CORPORATION (US) | 1984-03-27 | — | — | US | disclosed |
| US-4326525-A | Osmotic device that improves delivery properties of agent in situ | ALZA CORPORATION (US) | 1982-04-27 | — | — | US | disclosed |